{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:38:41Z","timestamp":1792550321675,"version":"4.5.0"},"reference-count":0,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp;amp; Rheumatology"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In APEX, guselkumab, which binds to the IL\u201023p19 subunit and CD64 on IL\u201023\u2010producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The APEX modified full analysis set included 1020 biologic\u2010na\u00efve adults with active PsA (\u22653 tender joints; \u22653 swollen joints; CRP \u22650.3mg\/dL; \u22652 erosive joints) randomized to guselkumab every (Q)4W (N=273), guselkumab at W0,4 then Q8W (N=371), or placebo followed by guselkumab Q4W beginning at W24 (N=376). Outcomes through W48 included ACR20\/50\/70 response rates (using multiple\/nonresponder imputation); least squares mean (LSM) change in PsA\u2010modified van der Heijde\u2010Sharp score (vdH\u2010S); achievement of clinically meaningful improvement (CMI; \u22650.35\u2010point) in HAQ\u2010DI, \u226590% improvement in Psoriasis Area and Severity Index (PASI90), and minimal disease activity (MDA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through W48, 93% (950\/1020) of participants completed study intervention. Guselkumab Q4W and Q8W through W48 demonstrated durable ACR20\/50\/70 response rates (71\u201074%\/51\u201056%\/31\u201035%), and low rates of structural damage progression (vdH\u2010S LSM change: 0.60\u20100.78); 60\u201064% of participants reported HAQ\u2010DI CMI, 74\u201080% achieved PASI90, 36\u201041% achieved MDA. Following transition to guselkumab, structural damage progression among placebo\u2010randomized participants diminished (vdH\u2010S LSM change W0\u201024: 0.96; W24\u201048: 0.41) and clinical response rates increased through W48. Adverse event rates were consistent with placebo and guselkumab through W24 and stable through W48 of guselkumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>APEX W48 findings further support guselkumab use for durable and comprehensive treatment of diverse PsA manifestations. Inhibition of cumulative joint damage with guselkumab may optimize outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70380","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:00:21Z","timestamp":1792548021000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic\u2010Na\u00efve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double\u2010Blind, Placebo\u2010Controlled\n                    <scp>APEX<\/scp>\n                    Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"first","affiliation":[{"name":"Department of Medicine, Allergy\/Immunology and Rheumatology University of Rochester Medical Center  Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research, Providence Swedish Medical Center  Seattle WA USA"},{"name":"University of Washington School of Medicine  Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford  Botnar Research Centre Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bensley","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koeun","family":"Im","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattandeep","family":"Batra","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Horsham  PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Horsham  PA USA"},{"name":"Drexel University College of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[{"name":"Craig L Dobbin Genetics Research Centre, Faculty of Medicine, Division of Rheumatology Memorial University of Newfoundland  St. John 's NL Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,20]]},"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:00:22Z","timestamp":1792548022000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":0,"alternative-id":["10.1002\/art.70380"],"URL":"https:\/\/doi.org\/10.1002\/art.70380","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"art.70380"}}